**Section: Contact Information**

First Name: **Jennifer**  
Last Name: **Yeh**  
Institution: **Harvard T.H. Chan School of Public Health**  
Address 1: **718 Huntington Avenue**  
City: **Boston**  
State/Province/Region: **MA**  
Country: **US**  
Zip/Postal Code: **02115**  
Phone Number: **617-432-2013**  
Email Address: **jyeh@hsph.harvard.edu**

**Section: Project Requirements and Description**

**Group: Requirements to submit AOI**

A comprehensive review of previously published data has been completed. : **Yes**  
The specific aims are clear and focused. : **Yes**  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**  
Project Title: **Developing a microsimulation model of the lifetime clinical course of childhood cancer**

Planned research population (eligibility criteria):  
**CCSS individuals diagnosed between 1970 and 1999**

Proposed specific aims:

**Aim 1.** Develop a microsimulation model of the lifetime clinical course of childhood cancer from diagnosis to death (from initial cancer, late effects or competing mortality).

**Aim 2.** Use the model to assess whether genetic testing at time of cancer diagnosis can improve risk stratification for treatment and follow-up care recommendations. Motivated by recently identified genetic variants associated with anthracycline-related cardiotoxicity, we will initially focus on CHF outcomes.

Will the project require non-CCSS funding to complete? : **Yes**

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :  
**NCI R01 application for the Feb 5, 2016 receipt date.**

**Group: Does this project require contact of CCSS study subjects for:**

Additional self-reported information: **No**  
Biological samples : **No**
Medical record data: No
If yes to any of the above, please briefly describe:

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)
Second Malignancy: [Primary]
Chronic Disease: [Primary]
Psychology / Neuropsychology: [Secondary]
Genetics: [Secondary]
Cancer Control: [Secondary]
Epidemiology / Biostatistics: [Secondary]

Section: Outcomes or Correlative Factors
Late mortality: [Primary]
Second Malignancy:

Group: Health Behaviors
Tobacco:
Alcohol:
Physical activity:
Medical screening:
Other:
If other, please specify:

Group: Psychosocial
Insurance:
Marriage:
Education:
Employment:
Other:
If other, please specify:

Group: Medical Conditions
Hearing/Vision/Speech:
Hormonal systems:
Heart and vascular:
Respiratory:
Digestive:
Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

Group: Medications
Describe medications:

**Group: Psychologic/Quality of Life**
- BSI-18:
- SF-36: Primary
- CCSS-NCQ:
- PTS:
- PTG:
- Other:
  If other, please specify:

**Group: Other**
- Pregnancy and offspring:
- Family history:
- Chronic conditions (CTCAE v3): Primary
- Health status:

**Group: Demographic**
- Age: Correlative Factors
- Race: Correlative Factors
- Sex: Correlative Factors
- Other:
  If other, please specify:

**Group: Cancer treatment**
- Chemotherapy: Correlative Factors
- Radiation therapy: Correlative Factors
- Surgery: Correlative Factors

**Section: Anticipated Sources of Statistical Support**
- CCSS Statistical Center: Yes
- Local institutional statistician: Yes
  If local, please provide the name(s) and contact information of the statistician(s) to be involved.
  
  Zachary Ward (zward@hsph.harvard.edu) - Computer Programmer
  Wendy Leisenring for CCSS statistical support

- Will this project utilize CCSS biologic samples?: No
  If yes, which of the following?:
  If other, please explain:

**Section: Other General Comments**
- Other General Comments:
  We would like to request individual-level CCSS data to develop our proposed microsimulation model of the clinical course of childhood cancer.
CCSS data will be used to develop the late-effects component of the simulation model. Data for the initial cancer treatment and genetic testing pieces will be based on published clinical studies and other data sources (not CCSS data).